Latest Quark Pharmaceuticals Inc. Stories
FREMONT, Calif., Jan. 4, 2012 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced interim results from the first two cohorts of its Open Label, first-in-human Phase I clinical study of QPI-1007, the Company's proprietary synthetic siRNA drug candidate for ocular neuroprotection, in patients with recent onset of non-arteritic anterior ischemic optic neuropathy (NAION). QPI-1007 exhibited no dose...
Rutgers researchers have developed an innovative new treatment that could help minimize nerve damage in spinal cord injuries, promote tissue healing and minimize pain.After a spinal cord injury there is an increased production of a protein (RhoA) that blocks regeneration of nerve cells that carry signals along the spinal cord and prevents the injured tissue from healing.Scientists at the W.M. Keck Center for Collaborative Neuroscience and Quark Pharmaceuticals Inc. have developed a chemically...
LONDON, April 27, 2011 /PRNewswire-FirstCall/ -- Silence Therapeutics Plc (AIM: SLN), a leading international RNAi therapeutics company, today announces its results for the year ended 31 December 2010. Analyst Conference Call: There will be a call for analysts today at 14:30 BST / 09:30 ET. The conference call can be accessed by dialling: Europe: +44(0)20-7136-2055 U.S.: +1-212-444-0896 Participant PIN...
LONDON, March 21, 2011 /PRNewswire-FirstCall/ -- Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company") a leading global RNA interference (RNAi) therapeutics company, announces today that its partner, Quark Pharmaceuticals, has received results from a prospective randomized Phase 2 trial, the DEGAS study. The study evaluated the safety and efficacy of PF-04523655 (RTP801I- 14) in patients with diabetic macular edema (DME). PF-04523655 incorporates Silence's AtuRNAi technology...
FREMONT, Calif., March 18, 2011 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a pharmaceutical company engaged in the discovery and development of RNAi-based therapeutics, today announced that it has received results from a prospective randomized Phase 2 trial, the DEGAS study. This study evaluated the safety and efficacy of PF-04523655 (RTP801I-14) in patients with diabetic macular edema (DME). 184 patients were randomly assigned to four treatment groups; three dose levels of PF-04523655...
LONDON, Dec. 21, 2010 /PRNewswire/ -- Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company"), a leading global biotechnology company dedicated to the discovery, development and delivery of targeted, systemic RNA interference (RNAi) therapeutics for the treatment of serious diseases, today provides a year-end update on trading and the offer-period. Phil Haworth, CEO of Silence Therapeutics, comments: "2010 has been an exciting year for Silence Therapeutics. The Company is delighted...
FREMONT, Calif., Oct. 20 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a pharmaceutical company engaged in the discovery and development of RNAi-based therapeutics, today announced it has dosed the first patient with recent onset of non-arteritic anterior ischemic optic neuropathy (NAION) in its ongoing Phase I study of QPI-1007, the Company's proprietary synthetic siRNA drug candidate for ocular neuroprotection. The Phase I open-label, dose-escalation study was initiated during the first...
LONDON, Aug. 19 /PRNewswire/ -- Silence Therapeutics plc (AIM: SLN), a leading international RNAi therapeutics company, is pleased to note that its partner, Quark Pharmaceuticals, Inc. ("Quark"), has announced the grant of an option to Novartis to obtain an exclusive worldwide license to develop and commercialise QPI-1002, a p53 temporary inhibitor siRNA drug which incorporates Silence's AtuRNAi technology. Quark is currently conducting a Phase II clinical trial of QPI-1002 for the...
FREMONT, Calif., Aug. 18 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced that it has granted Novartis an option to obtain an exclusive worldwide license to develop and commercialize its p53 temporary inhibitor siRNA drug QPI-1002, currently the subject of a Phase II clinical trial. Quark will receive initially a non-refundable fee of 10 million USD. In the event that Novartis exercises the option, Quark...
OSAKA, Japan and FREMONT, Calif., July 15 /PRNewswire/ -- Nitto Denko Corporation, Japan's leading diversified materials manufacturer and Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced the initiation of a collaboration and license agreement for the development of siRNA therapeutics for the treatment of fibrotic diseases. The collaboration is designed to develop siRNA drugs using Quark's RNAi technologies and novel...
